Rasagiline (Azila) usually takes a few days to see initial effects.

Rasagiline (Rasagiline) is a selective monoamine oxidase-B (MAO-B) inhibitor. It is mainly used for the early treatment of Parkinson's disease or in combination with levodopa for advanced patients. By inhibiting MAO-B activity, it can delay the decomposition of dopamine in the brain, thereby increasing dopamine levels, improving symptoms such as tremor, stiffness, and bradykinesia, and helping patients restore their daily activities.

In most patients, the initial efficacy of rasagiline usually begins around 7 to 14 days. Patients may experience relief from bradykinesia, less stiffness, and slightly improved mobility. However, due to individual differences, the time it takes for symptoms to improve may vary, and some patients may take longer to notice the effects.

It should be noted that the optimal efficacy of rasagiline usually takes several weeks to a month or even longer to be stably manifested. During this period, the patient should take the medication regularly every day as directed by the doctor and is not allowed to increase or decrease the dose or stop the medication on his own. At the same time, you should cooperate with your doctor to regularly evaluate symptom changes and drug tolerance, and judge the efficacy by observing the improvement in daily life abilities.

To ensure medication safety and efficacy, patients can record daily changes in symptoms, such as tremor, stiffness, mobility, and sleep status. If there is no significant improvement after about a month, you should communicate with your doctor in time to evaluate whether the treatment plan needs to be adjusted or combined with other drugs. Through standardized medication and reasonable monitoring, rasagiline can exert the best therapeutic effect within a safe range and provide stable movement improvement and quality of life improvement for patients with Parkinson's disease.

Reference link:https://www.drugs.com